Article Text

PDF
Therapeutics
Real-time continuous glucose monitoring improves glycaemic variability and neonatal outcomes in pregnant women with type 1 diabetes
  1. Sally K Abell,
  2. Sophia Zoungas
  1. Monash Centre for Health Research and Implementation, Monash University, Clayton, Victoria, Australia
  1. Correspondence to Professor Sophia Zoungas, Monash Centre for Health Research and Implementation, Monash University, Clayton VIC 3800, Australia; Sophia.Zoungas{at}monash.edu

Statistics from Altmetric.com

Commentary on: Feig DS, Donovan LE, Corcoy R, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet 2017;390(10110):2347-59.

Context

Risk of adverse obstetric and neonatal outcomes in pregnant women with type 1 diabetes can be reduced with more intense glycaemic control,1 but achieving targets is challenging. Indeed, with specialist input, only 40% of women achieve optimal glycaemic control during pregnancy.2

Real-time continuous glucose monitoring (rt-CGM) provides rich information on direction and rate of change of interstitial glucose. This assists patients to modify behaviours, diet, exercise and insulin dosing with immediate feedback and corrective actions possible to minimise glucose excursions. To date, randomised trials of CGM in pregnancy have been limited.

Methods

CONCEPTT is a multicentre open-label randomised controlled trial (RCT) of reproductive age women with type 1 diabetes on intensive insulin therapy.3 Women in the first trimester …

View Full Text

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.